ScreenerHero
B8FKBiofrontera AGPartial data
XETRA · DE · Healthcare · Drug Manufacturers - Specialty & Generic · biofrontera.com
2.540EUR-1.17%Mkt Cap: 16.78M $P/E: —

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
HeadlineSourceTime
Older
Biofrontera AG Aktie: Earnings & Quartalszahlen
Goldesel.de
PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
FinanzNachrichten.de
Biofrontera Inc (BFRI) Aktionärsstruktur: Hauptaktionäre & institutionelle Bestände
TTradingKey
Biofrontera Aktie: FDA-Entscheidung im September 2026
Börse Express
PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026
FinanzNachrichten.de
Biofrontera Aktie: Fokus Earn-outs
Börse Express
Paradigmenwechsel in der onkologischen Dermatologie: Vidac Pharma als Innovator, was machen Almirall und Biofrontera?
inv3st.de
Biofrontera AG Aktie Kurs & Chart A4BGGM
Goldesel.de
Biofrontera veräußert US-Lizenz für Xepi für bis zu 10 Millionen US-Dollar
Investing.com Deutsch
Biofrontera Inc. close purchase of all Ameluz, RhodoLED U.S. assets

Biofrontera Inc. (BFRI) announced the closing of its restructuring and asset purchase agreement with its former parent company, Biofrontera AG. Under the transaction, Biofrontera Inc. has acquired all U.S. assets and rights related to Ameluz and RhodoLED, including the New Drug Application, Investigational New Drug Application, manufacturing rights and contracts, all intellectual property, and related personnel. As a result of the transaction, Biofrontera Inc. will now pay a monthly earnout of 1

TipRanks
Will Biofrontera (ETR:B8FK) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St.
Biofrontera (WKN A4BGGM, ISIN DE000A4BGGM7) - Aktien, Börse, Aktienkurse, Börsenkurse
AAriva